Shots:
- The P-III (TEMPLE) trial assessed Qulipta (60mg, QD) vs the highest tolerated dose of topiramate (50, 75 or 100mg; QD) over 24wks. in 545 adults with ≥4 monthly migraine days (MMD) across 73 sites in the EU, Israel & Canada, followed by a 52wk. open-label phase, where all pts received Qulipta
- Trial met its 1EP, with significantly fewer AE-related discontinuations (12.1% vs 29.6%), representing a relative risk of 0.41 & also achieved all six 2EPs, incl. 64.1% vs 39.3% pts attaining ≥50% reduction in mean MMD during 4 to 6mos.; data to be presented at future meetings
- Atogepant is a CGRP receptor antagonist developed for migraine prevention in adults & is marketed as Aquipta in the EU & as Qulipta in the US, Canada, Israel & Puerto Rico
Ref: Prnewswire | Image: Abbvie| Press Release
Related News:- Camurus Reports Topline P-IIb (POSITANO) Trial Data on CAM2029 for Symptomatic Polycystic Liver Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
